Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Becker, M; Szarvas, T; Wittschier, M; Vom Dorp, F; Tötsch, M; Schmid, KW; Rübben, H; Ergün, S.
Prognostic impact of plasminogen activator inhibitor type 1 expression in bladder cancer.
Cancer. 2010; 116(19):4502-4512
Doi: 10.1002/cncr.25326
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Tötsch Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Recent studies have demonstrated a poor prognosis for patients who have altered expression of plasminogen activator inhibitor type 1 (PAI-1) in several cancer types. The objective of the current study was to investigate the prognostic impact of PAI-1 on patients with transitional cell carcinoma (TCC) of the urinary bladder. METHODS: PAI-1 expression was quantified using real-time polymerase chain reaction in 91 TCCs and in 6 normal tissue specimens. PAI-1 concentrations were analyzed by enzyme-linked immunoadsorbent assay in plasma from 104 patients and 10 controls and in urine from 244 patients and 74 controls. PAI-1 expression was evaluated immunohistochemically in paraffin-embedded tissues (94 tumor samples and 10 adjacent normal tissue samples). The results were analyzed in relation to clinical features and follow-up. RESULTS: Significantly higher PAI-1 levels were detected in tissue and plasma samples, but not in urine, from patients with bladder cancer compared with controls (P=.001 and P=.008, respectively). Elevated gene expression and plasma protein concentrations were independent of tumor stage and grade. Immunostaining revealed a subgroup of patients with single tumor cells that strongly expressed PAI-1. These patients' survival was significantly shorter, and their clinical presentation was correlated significantly with lymph node-positive disease. CONCLUSIONS: PAI-1 gene expression in tissues and plasma protein levels were elevated in patients with TCC compared with controls. PAI-1 gene or protein expression was not associated with the clinical characteristics of bladder TCC. Although the assessment of PAI-1 expression in plasma or urine may not serve as an independent predictor of prognosis in patients with TCC, the immunohistochemical detection of single PAI-1-positive cells may serve as a predictor of survival and a possible indicator of metastasis. Cancer 2010;116:4502-12. (C) 2010 American Cancer Society.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Carcinoma, Transitional Cell - diagnosis Carcinoma, Transitional Cell - metabolism Carcinoma, Transitional Cell - mortality
- Female -
- Humans -
- Immunohistochemistry -
- Male -
- Middle Aged -
- Plasminogen Activator Inhibitor 1 - blood Plasminogen Activator Inhibitor 1 - metabolism Plasminogen Activator Inhibitor 1 - urine
- Prognosis -
- Tumor Markers, Biological - analysis
- Urinary Bladder Neoplasms - diagnosis Urinary Bladder Neoplasms - metabolism Urinary Bladder Neoplasms - mortality
- Find related publications in this database (Keywords)
- biomarker
- bladder cancer
- plasminogen activator inhibitor type 1
- prognosis
- survival